The pathophysiology theory of migraine postulates a local, neurogenic inflammation and the possible involvement of oxidative stress. We analysed the levels of 15-oxo-dihydro-prostaglandin F 2α (a metabolite of prostaglandin F 2α ) and 8-iso-prostaglandin F 2α (a major isoprostane), which are biomarkers for inflammation and oxidative stress respectively, in urine from 21 patients with migraine, with and without aura. Urine samples from migraine patients were collected during a migraine attack, and control samples were collected from the same subjects on a migraine-free morning. The mean basal levels of 15-oxo-dihydro-prostaglandin F 2α and 8-iso-prostaglandin F 2α in the morning control urine samples were 0.54p0.11 and 0.31p0.13 nmol/mmol of creatinine respectively. The mean levels of 15-oxo-dihydro-prostaglandin F 2α and 8-iso-prostaglandin F 2α in the urine samples collected during the migraine attack in the 21 patients were 0.53p0.13 and 0.32p0.11 nmol/mmol of creatinine respectively. Thus there were no differences in the 15-oxodihydro-prostaglandin F 2α and 8-iso-prostaglandin F 2α excretion rates during the migraine attack compared with on the migraine-free day. However, the basal 8-iso-prostaglandin F 2α excretion levels on the migraine-free day were significantly lower in pre-menopausal women (0.24p0.08 nmol/mmol of creatinine, n l 11) compared with post-menopausal women (0.39p0.14 nmol/mmol of creatinine ; n l 7; P l 0.009). In conclusion, in this study we found no support for the involvement of inflammation and oxidative stress in migraine pathophysiology. Our results indicate, however, a lower level of oxidative stress in pre-menopausal compared with post-menopausal women.
INTRODUCTION
Migraine is a common disorder characterized by attacks of headache. Some patients experience a preceding visual disturbance (migraine with aura). Many authors believe that sterile inflammation within the trigeminovascular system is of great importance in the pathophysiology of migraine pain. This model (the neurogenic inflammation model) postulates release of the neurotransmitter substance P, vasodilatation, increased permeability, oedema of cranial blood vessels and sensitization to pain [1] .
Several biochemical mediators have been implicated in the pathogenesis of migraine, such as calcitonin-generelated peptide [2] , nitric oxide [3] and prostaglandins [4] .
Only a few attempts have been made so far to measure prostaglandin-related compounds during the migraine pain phase. However, prostaglandin E # (PGE # ) and thromboxane A # levels in saliva have been found to be elevated during migraine attacks [5] . Increased levels of plasma PGE # were found during the pain phase in women with menstrual migraine [6] . Plasma levels of nonesterified fatty acids, in particular linoleic acid (a pre-cursor of arachidonic acid), have been found to be elevated during migraine attacks [7, 8] , possibly indicating an increased involvement of pathways using arachidonic acid as a substrate during a migraine attack. Cyclooxygenase inhibitors, e.g. acetylsalicylic acid and other NSAIDs (non-steroidal anti-inflammatory drugs), are effective in relieving migraine pain, suggesting an important role for eicosanoids in the pathogenesis of migraine [9] .
The level of 15-oxo-dihydro-PGF # α , a major metabolite of PGF # α in plasma, is increased during the inflammatory response, and is considered to be a reliable biomarker of inflammation [10] . Oxidative stress is known to be induced during acute inflammation in animal models [11, 12] . Further, nitric oxide has the potential to induce oxidative stress by acting as a free radical through the peroxynitrite pathway. Isoprostanes are formed by the free radical-catalysed peroxidation of arachidonic acid in the presence of oxidative stress. 8-Iso-PGF # α is a major isoprostane that is formed, and this metabolite is considered to be a reliable marker of oxidative injury in both animals and humans [13, 14] .
The aim of the present study was to investigate if inflammation and oxidative stress are involved in the pathological process of migraine. We analysed the excretion of 15-oxo-dihydro-PGF # α and 8-iso-PGF # α in urine samples, as indicators of inflammation and oxidative stress respectively, collected during a migraine attack and on a migraine-free morning.
MATERIALS AND METHODS

Study design
A total of 21 patients with a clinical diagnosis of migraine, with or without aura [15] , from the Outpatients Clinic of the Centre of Clinical Neuroscience, Uppsala University Hospital, agreed to participate in the study. The participants were asked to collect a urine sample 20-30 min after their migraine headache had started, and one control urine sample on a migraine-headache-free morning, with at least 2 days between collection of the samples. They were informed not to take any NSAIDs prior to the urine collections. The samples were stored frozen immediately at approx. k20 mC and delivered to our laboratory as soon as possible. The urine samples were then stored frozen at k70 mC until analysis.
The participants were asked to fill in a questionnaire about medication, menstrual cycle\pregnancy, diseases other than migraine, physical training 24 h prior to the urine collections, and the symptoms of the migraine attack during which the urine sample was collected. The study was approved by the Ethics Committee, Faculty of Medicine, Uppsala University, and all subjects gave informed consent.
Patients
The participants were 18 women and three men with a mean age of 47 years (range 24-63 years). None of the patients smoked, had diabetes mellitus or displayed clinical symptoms of ischaemic heart disease. Seven women were post-menopausal and 11 were pre-menopausal. Among the pre-menopausal group, three women were close to the menopause and were taking regular hormone replacement therapy (medium-potency oestrogens). Three women were taking combined contraceptive pills (ethinyloestradiol and desogestrel\norethisterone), one woman had a hormone spiral (levonorgestrel) without ovulations, one woman was taking minipills (low norethisterone dose) with ovulations, and the rest of the pre-menopausal women had menstrual cycles and no hormone preventatives.
Chemicals
Unlabelled 15-oxo-dihydro-PGF 
$H-labelled 15-oxo-dihydro-PGF
# α (specific radioactivity 6.77 TBq : mmol −" ) was obtained from Amersham (Little Chalfont, Bucks., U.K.). Antibodies against 15-oxo-dihydro-PGF # α and 8-iso-PGF # α were raised at our laboratory and well characterized [10, 16] .
RIA of urinary 15-oxo-dihydro-PGF 2α
The urine samples (50 µl) were analysed for 15-oxodihydro-PGF # α by a newly developed RIA in our laboratory, as described elsewhere [10] . In brief, an antibody was raised in rabbits by immunization with 15-oxo-dihydro-PGF # α coupled to BSA at the carboxylic acid group using the 1,1h-carbonyldi-imidazole method. The cross-reactivity of the antibody with
# and 8-iso-PGF $ α was 0.02 %, 0.43 %, 0.001 %, 0.5 %, 1.7 %, 0.001 %, 0.001 %, 0.001 % and 0.01 % respectively. The limit of detection was approx. 45 pmol\l.
RIA of urinary 8-iso-PGF 2α
The urine samples (50 µl) were analysed for free 8-iso-PGF # α without any prior extraction or purification by a newly developed RIA [16] . In brief, an antibody was raised in rabbits by immunization with 8-iso-PGF # α coupled to BSA at the carboxylic acid by the 1,1h-carbonyldi-imidazole method. The cross-reactivity of the antibody with 8-iso-15-oxo-13,14-dihydro-PGF
-PGF # α and 8-iso-PGF $ α was 1.7 %, 9.8 %, 1.1 %, 0.01 %, 0.01 %, 0.1 %, 0.03 %, 1.8 % and 0.6 % respectively. The limit of detection of the assay was approx. 23 pmol\l.
Urine creatinine assay
The creatinine concentration was determined in each urine sample by a colorimetric method using IL Test creatinine 181672-00 in a Monarch2 2000 centrifugal analyser (Instrumentation Laboratories, Lexington, MA, U.S.A.). The levels of 8-iso-PGF # α and 15-oxo-dihydro-PGF # α in urine were corrected for urine creatinine values.
Statistics
All results are expressed as meanspS.D. Paired t-tests were used to examine differences in the levels of 15-oxodihydro-PGF # α and 8-iso-PGF # α between the control and migraine samples. Unpaired t-tests were used for testing differences between pre-menopausal and postmenopausal women with regard to basal levels of 15-oxodihydro-PGF # α and 8-iso-PGF # α . Data for 8-iso-PGF # α and age had a skewed distribution according to the Shapiro-Wilks test, and were log-transformed. Since age data still had a skewed distribution after transformation, the Mann-Whitney test was used to test the difference between the two groups of women. All tests were twotailed, and P 0.05 was regarded as statistically significant. All calculations were performed using the statistical software package JMP (version 3.2 ; SAS Institute, Cary, NC, U.S.A.).
RESULTS
The symptoms reported during the migraine attack by each patient were in accordance with the migraine criteria [15] . Seven patients reported vision disturbances, in the form of scintillating scotomas, prior to the migraine headache. The migraine urine sample was collected on 
15-Oxo-dihydro-PGF 2α and 8-iso-PGF 2α levels
The mean basal levels of 15-oxo-dihydro-PGF # α and 8-iso-PGF # α in the control urine samples collected on a migraine-headache-free morning for all 21 patients were 0.54p0.11 and 0.31p0.13 nmol\mmol of creatinine respectively. The mean levels of 15-oxo-dihydro-PGF # α and 8-iso-PGF # α in the urine samples collected during the migraine attack for all patients were 0.53p0.13 and 0.32p0.11 nmol\mmol of creatinine respectively. These levels measured in urine collected during a migraine attack were not different from the basal urinary levels of 15-oxo-dihydro-PGF # α (P l 0.87) and 8-iso-PGF # α (P l 0.67).
The pre-menopausal women (with either synthetic or physiological sex hormones) had a significantly lower basal level of excretion of 8-iso-PGF 
DISCUSSION
In the present study, no altered excretion of a PGF # α metabolite or an F # -isoprostane was seen during a migraine attack, indicating no major involvement of inflammation or oxidative injury in these patients. The basal levels of PGF # α metabolite and F # -isoprostane in urine from patients with migraine were in the same range as described in our earlier study of healthy men and women [17] .
The possibility exists that a local inflammatory response and subsequent eicosanoid release during the migraine attack may not have been extensive enough to be detected by measuring urinary excretion of metabolites. Further, minor increases in the levels of these compounds may be missed by the urinary measurement protocol unless frequent blood sampling is also performed. This is due mainly to the very short half-lives of 8-iso-PGF # α , primary PGF # α (the parent compound of 15-oxo-dihydro-PGF # α ) and 15-oxo-dihydro-PGF # α .
Therefore there is a risk that we may have missed any minor increase in the excretion of these compounds because of difficulties in timing a spot urine sample. If the migraine pain is a consequence of inflammation and oxidative stress, a rapid increase in the levels of these compounds would be expected at an early stage during the migraine attack. A study design involving frequent collection of plasma samples during a migraine attack would probably give more information with regard to any mild inflammation occurring during the attack, but this is difficult to achieve for practical and ethical reasons.
More than half of the patients were taking various NSAIDs on a regular basis that may have affected the levels of the PGF # α metabolites. However, since the halflife of the NSAIDs used is approx. 2-3 h, and since only one subject took NSAIDs prior to the urine collection, the effect of the regular intake of NSAIDs is likely to be very small. The fact that the control urine sample was collected in the morning reduces the risk of an influence of medication. According to our present knowledge, the risk of affecting the isoprostane levels by consuming NSAIDs is limited in humans. A study of smokers and non-smokers taking aspirin showed no effect on urinary isoprostane levels [18] , which is reasonable, since the pathway of formation of isoprostanes is primarily via non-enzymic free radical-induced lipid peroxidation [13] . Thus it is unlikely that large differences in PGF # α metabolite and F # -isoprostane levels would have gone undetected.
We found that pre-menopausal women had significantly lower basal levels of 8-iso-PGF # α than postmenopausal women. Studies of oestrogens acting as inhibitors of oxidation of low-density lipoprotein suggest that oestrogens do possess antioxidative properties. This has been described for various kinds of oestrogen compounds, including conjugated equine oestrogens in post-menopausal women [19] and 17β-oestradiol in physiologically relevant concentrations for menstruating women given to post-menopausal women [20] and added to plasma from pre-menopausal women [21] . The premenopausal group of women in our study consisted of women with menstruation cycles, women prescribed ethinyl oestradiol and women prescribed oestrogen compounds of medium potency, including conjugated equine oestrogen. There is a well-described reduced risk of cardiovascular disease in pre-menopausal compared with post-menopausal women [22] and for peri-menopausal women prescribed non-contraceptive oestrogen [23] observed in epidemiological studies. The reduced level of F # -isoprostane in the urine of pre-menopausal women found in the present study gives further support to an antioxidative effect of oestrogen, possibly explaining part of the well-known difference in the incidence of cardiovascular disease between pre-and post-menopausal women. Further, no difference in the basal levels of the prostaglandin metabolite was seen between the pre-and post-menopausal women, suggesting that levels of enzymically derived prostaglandins are not altered by the menopause.
In conclusion, the present study does not support the hypothesis that inflammation or oxidative stress is part of the pathogenesis of migraine. The basal levels of 15-oxodihydro-PGF # α and 8-iso-PGF # α in patients with migraine are not different from those in healthy humans. However, there is significantly decreased excretion of 8-iso-PGF # α in pre-menopausal women compared with post-menopausal women, indicating a lower occurrence of oxidative stress in these women, possibly due to the antioxidative effect of oestrogen.
